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SUMMARY
Familial hypercholesterolaemia (FH) contributes significantly to the high death rate
from cardiovascular disease worldwide. FH is a common autosomal co-dominant
disease characterised by raised cholesterol levels and premature coronary heart
disease (CHD). Whilst these features usually are very prominent in homozygotes the
clinical diagnosis of heterozygotes is complicated by variable phenotypic expression.
Specific founder genes in the low-density lipoprotein receptor (LDLR) gene have
increased the prevalence of FH in South African Afrikaners, Indians, Jews and
Coloureds, and screening for these known mutations allows unequivocal diagnosis
of FH-affected individuals. The systematic molecular analysis of FH resulted in the
identification of at least ten founder-type LDLR gene mutations among the 56
different gene defects described to date in the diverse South African population.
DNA screening of 792 at-risk family members for the FH-related mutations identified
in 379 index cases, allowed accurate disease diagnosis in an additional 340
relatives and exclusion of the relevant mutation in 452 individuals. This effort forms
part of the MED PED FH initiative, a collaborative project to "Make Early Diagnosis
and Prevent Early Deaths in MEDical PEDigrees with FH".
Evaluation of clinical criteria versus DNA diagnosis of three founder-related
mutations (D154N, D206E and V408M) in the South African population
demonstrated that the sensitivity and specificity of diagnoses, based on total
cholesterol values measured in family members of index cases recruited for this
study, were 88% and 77%, respectively. A population-directed DNA diagnosis of FH
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is therefore justified in South Africa on a routine basis, since expression of the
defective gene measured in biochemical tests does not allow accurate diagnosis of
FH in all cases.
The application of mutation detection was illustrated by prenatal diagnosis of FH
performed for a couple who are both heterozygous for the most common Afrikaner
mutation, D206E. The mutation was absent in the foetus and a
normocholesterolaemic infant was born. Prenatal diagnosis of FH, aimed at the
detection of homozygous cases, is particularly applicable in populations and families
with molecularly defined LDLR gene mutations.
The MED-PED approach resulted in accurate diagnosis and subsequent treatment
of FH in more patients, and referral to lipid clinics where they could receive the
intensive care their condition justifies. Molecularly diagnosed FH patients will be the
first to benefit from future treatment approaches based on mutation type.
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OPSOMMING
Familiële hiprcholesterolemie dra grootliks by tot die wêreldwye hoë sterftesyfer van
kardiovaskulêre siekte. FH is 'n algemene outosomale ko-dominante siekte wat
gekenmerk word deur verhoogde cholesterolvlakke en vroeë koronêre hartsiekte.
Terwyl hierdie kenmerke prominent is in homosigote, word die kliniese diagnose van
heterosigote bemoeilik deur variasie in fenotipiese uitdrukking. Spesifieke
stigtergene in die lae-digtheids lipoproteien reseptor (LDLR) geen het die
voorkomssyfer van FH verhoog in Suid Afrikaanse Afrikaners, Indiërs, Jode en
Kleurlinge. Sifting vir hierdie bekende mutasies maak akkurate diagnose van FH-
geaffekteerde individue moontlik. Die sistematiese molekulêre analise van FH het
aangetoon dat ten minste tien van die 56 verskillende geen defekte wat tot dusver
beskryf is in die Suid-Afrikaanse populasie stigtertipe LDLR geen mutasies is. DNA
sifting van 792 familielede vir die FH-verwante mutasie in 379 indeksgevalle
geïdentifiseer is, het akkurate diagnose moontlik gemaak in 340 addisionele
familielede, en uitsluiting daarvan in 452 individue. Hierdie poging vorm deel van die
MED-PED FH ("Make Early Diagnosis and Prevent Early Deaths in MEDical
PEDigrees with FH) inisiatief.
Evaluering van kliniese kriteria teenoor DNA diagnose van drie stigter verwante
mutasies (D154N, D206E en V408M) in die Suid Afrikaanse populasie het getoon
dat die sensitiwiteit en spesifisiteit van die diagnose, wat gebasseer is op totale
cholesterol waardes in familielede van indeksgevalle, onderskeidelik 88% en 77%
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was. 'n Populasie gerigte DNA diagnose van FH is dus geregverdig in Suid-Afrika op
"n roetine basis, omdat die defektiewe geen nie altyd in biochemiese toetse
uitgedruk word nie.
Die waarde van mutasie opsporing is geillustreer deur 'n voorgeboortelike diagnose
van FH wat aangevra is vir ouers wat beide heterosigoties is vir die mees algemene
Afrikaner mutasie, D206E. Die mutasie was afwesig in die fetus en 'n
normocholesterolemiese baba is gebore. Voorgeboortelike diagnose van FH, wat
gemik is op die opsporing van homosigotiese gevalle, is veral van toepassing in
populasies en families met bekende LDLR geen mutasies.
Die MED-PED benadering het gelei tot akkurate diagnose en daaropvolgende
behandeling van FH in meer pasiënte, en verwysings na lipiedklinieke waar hulle
intensiewe aandag kan geniet. Molekulêre gediagnoseerde FH pasiënte sal die
eerste wees om baat te vind by toekomstige behandeling wat moontlik gebasseer
sal word op mutasie status.
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CHAPTER 1
INTRODUCTION
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1.1 The MED-PED Project
MED-PED (Make Early Diagnosis to Prevent Early Deaths in MEDical PEDigrees) is an
international project aimed at the identification of family members at risk of developing a
treatable dominantly inherited disorder. Following index case identification, many close
relatives are identified with the same genetic disease by this efficient and cost effective
family-based approach. In addition, education, treatment, long term support and
compliance are thought to be more effective when involving families instead of
individuals (Williams et al., 1993).
The common lipid disorder, familial hypercholesterolaemia (FH), represents an excellent
first model for the MED-PED approach. The goal is to identify persons with FH who are
undiagnosed and therefore not treated to protect or at least delay onset of coronary
heart disease (CHD). Only a small proportion of the estimated 10 million FH
heterozygotes and 5000 FH homozygotes worldwide are receiving the benefits of recent
advances in the diagnosis and treatment of FH. Heterozygous FH patients do not
require specialised experimental genetic treatment to live longer. Changes in diet and
administration of cholesterol-lowering drugs are relatively easy to implement. MED-PED
currently involves over 180 collaborators from at least 30 countries worldwide. FH cases
in the MED-PED registry has risen from 800 in 1994 to approximately 30 000 in 1998
(FH: report of a WHO consultation., 1997).
MED-PED provides a method to avoid costly general population screening, yet is
practical and easy to implement. The first step in a genetic approach is to obtain a blood
sample for DNA isolation and mutation screening of the low-density lipoprotein receptor
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2(LDLR) gene from an individual with a clinical diagnosis of FH. Once the disease-
causing mutation has been identified in the index patient, all relatives can be screened
for the gene defect. This allows presymptomatic diagnosis or exclusion of FH in at-risk
family members. Figure 1.1 illustrates the outline of the MED-PED approach. MED-PED
guidelines have been described and documented to be cost effective. Since treatment is
available for FH, patients should be identified and informed of the ability to significantly
reduce their risk of heart disease.
Clinically diagnosed FH patient
~
Collection of blood samples
~
DNA Isolation
~
Mutation Detection
~
Sequencing
~
Restriction Enzyme Digestion (where appropriate)
Detection of family-specific mutation(s) in MED-PED pedigrees
Figure 1.1 MED-PED approach for identification of FH mutations in families
Stellenbosch University http://scholar.sun.ac.za
3The MED-PED approach for case finding involves five different steps.
Step 1: Index case finding. This is the first person identified as having FH and
represents a newly discovered FH pedigree.
Step 2: Relative case finding. The index case is asked to give consent for MED-PED
staff to contact relatives who may have high plasma cholesterol levels and/or early CHD.
This family information is collected by various methods but usually involves the index
case providing information such as full names, addresses and telephone numbers of
their relatives.
Step 3: Diagnosis. Medical staff review patient and relative data and make a diagnosis
based on biochemical and/or mutation data.
Step 4: Enter in MED-PED registry. After an individual is diagnosed with FH, they are
notified and entered into the MED-PED registry.
Step 5: Continuation of relative case finding. After identifying family members with FH,
several new FH cases can be found among more distant relatives. The probability of a
family member carrying an LDLR mutation is well defined; the likelihood of having FH is
50% for each parent, sibling and child; 25% for each aunt, uncle, grandparent, niece and
nephew; 12.5% for first cousins and siblings of grandparents (FH: report of a WHO
consultation., 1997).
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4Other dominantly inherited diseases where the MEO-PEO approach can be applied
include familial defective apolipoprotein B (FOB) (clinically indistinguishable from FH),
sudden arrhythmic death syndrome (long QT), glucocorticoid remediable aldosteronism
(GRA) with hypertension and early strokes and possibly several cancers of the breast
and colon (Williams et al., 1993). In South Africa, this family-based approach has been
extended to identify affected relatives of patients suffering from several genetic diseases
that occur at increased frequencies due to founder gene mutations (Kotze and Callis,
1999).
1.2 Familial hypercholesterolaemia (FH)
The features of hypercholesterolaemia, xanthomatosis and angina pectoris, have been
recognised as a dominantly inherited disease since the work of MOiler in 1939. Further
studies outlined in Table 1.1 led to cloning of the LOLR gene underlying this common
lipid disorder. Heterozygous FH is characterised by a two-fold increase of cholesterol in
LOL. VLOL cholesterol and triglyceride levels may also occasionally be increased. The
increase of LOL cholesterol is seen even in childhood, usually being present already at
birth (Kwiterovich et al., 1974). Clinical symptoms of the disease include tendon
xanthomas, xanthelasma, arcus corneae and atherosclerosis. These symptoms usually
develop gradually from the second decade until the fourth decade of life. Half of all FH
heterozygotes develop xanthomas and arcus corneae by the third decade of life.
-,
Eventually 80% of FH patients will be affected with xanthomas. The complications
resulting from atherosclerosis are myocardial infarction and/or stroke. The mean age of
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5onset of CHO is about 45 years in affected males and 53 years in affected females
(Goldstein et al., 1995).
In the homozygous state this condition is much more severe with plasma LOL levels
elevated at least four times the normal value. Severe hypercholesterolaemia is present
at birth and persists throughout life. Xanthomas are sometimes present at birth but by
age 4 it is evident in nearly every patient. Arcus corneae develop in early childhood.
Atherosclerosis results in death from myocardial infarction usually before thirty years of
age (Goldstein et al., 1995).
The world prevalence of heterozygous FH is 1:500 and that of homozygotes is
1:1000000 (Goldstein et al., 1995). In certain homogeneous populations, such as the
South African Afrikaner population, the frequency is as high as 1/70 due to a founder
effect (Seftel et al., 1980; Steyn et al., 1996).
Stellenbosch University http://scholar.sun.ac.za
6Table 1.1 History of Familial Hypercholesterolemia (FH)
1784 Discovery of cholesterol
Pre 1900 Association of xanthomas in tendons and atheromas in arteries
1930s MOiler & Thannhauser recognised familial clustering of patients exhibiting
xanthomas, premature CHD and hypercholesterolaemia
1940s/50s Wilkinson and Aldersberg substantiated genetic basis for
hypercholesterolaemia by family studies
mid 1950s Gofman showed hypercholesterolaemia in FH due to a selective increase
in the plasma concentration of low density lipoprotein
early 1960s Khachadurian delineated differences between heterozygotes and
homozygotes - first evidence of a single gene inheritance
Fredrickson, Levy and Lees conclude that FH is a disorder involving the1960s
metabolism of both the apolipoprotein and cholesterol components of LDL
Brown and Goldstein discovered that FH is caused by mutations in the cell
surface LDLR gene
1982 Purification of the LDLR gene
1983 Cloning of the cDNA
1970s
1984 Isolation and characterisation of the gene at a locus on human
chromosome 19
1985 Brown and Goldstein were awarded the Nobel Prize in Medicine
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71.3 The low density lipoprotein receptor (LDLR)
The LOLR gene is located on the short arm of chromosome 19. The gene encodes a
single-chain cell-surface glycoprotein comprising 839 amino acids in its mature form. It
contains approximately two asparagine-linked oligosaccharide chains and nearly
eighteen serine/threonine-linked oligosaccharide chains. The LOLR binds two protein
ligands, apolipoprotein B-100 and apolipoprotein E (Schneider et al., 1982).
The mRNA of the LOLR is 5.3 kb long and encodes a protein of 860 amino acids. Nearly
half of the mRNA constitutes a long 3' untranslated region with two and a half copies of
the Alu family of middle repetitive DNAs. The gene is divided into 18 exons and 17
introns (Yamamoto et al., 1984).
The LOLR pathway starts in the endoplasmic reticulum (ER) where the protein is
synthesised. It contains high mannose N-linked carbohydrate chains and O-linked
chains. After 30 minutes the high mannose N-linked oligosaccharide chains are
converted to the complex endoglycosidase H-resistant form. At the same time, the
addition of one galactose and one or two sialic acid residues elongate each O-linked
chain. Next, the LOLRs appear on the cell surface where they gather in coated pits.
These coated pits then form coated vesicles. Many of these coated vesicles will fuse to
form endosomes. Due to a low pH, the receptor returns to the surface where it binds
<,
with another lipoprotein particle and begins another cycle of endocytosis. The LOL that
dissociates from the receptor moves to the lysosome, where it is degraded by acid
hydrolytic enzymes. The apoprotein of LOL is hydrolysed by a lysosomal lipase. The
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8unesterified cholesterol is used for membrane synthesis and as a regulator of
intracellular homeostasis (Soutar et al., 1986).
1.4 Classification of LOLR gene mutations
LDLR mutations can be divided into five classes based on their phenotypic effects on
the protein. Class 1 mutations fail to produce immunoprecipitable protein (null alleles).
Class 2 mutations encode proteins that are blocked, either completely or partially, in
transport between the ER and the Golgi apparatus (transport-defective alleles). Class 3
mutations encode proteins that are synthesised and transported to the cell surface, but
fail to bind LOL normally (binding-defective alleles). Class 4 mutations encode proteins
that move to the cell surface and bind LOL normally, but are unable to cluster in clathrin-
coated pits and thus do not internalise LOL (internalisation-defective alleles). Class 5
mutations encode receptors that bind and internalise in coated pits, but fail to discharge
the ligand in the endosome and fail to recycle to the cell surface (recycling-defective
alleles) (Hobbs et al., 1990; Goldstein et al., 1995).
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91.5 Aim of study
FH is a largely underdiagnosed disease and therefore most affected individuals are not
treated to prevent unnecessary early deaths due to heart attacks. Studies are ongoing to
identify the disease-causing mutation in index patients being referred for molecular
diagnosis, and tracing of the defective LDLR genes in families would enable accurate
diagnosis of FH or exclusion of the disease in at-risk family members. Most importantly,
it would identify those family members at high risk of developing CHD, so that
cholesterol levels can be lowered or normalised by dietary and/or drug treatment.
The objective of this study was to screen relatives of molecularly-characterised FH index
patients for a known mutation in the family, to incorporate this data in the MED-PED
database. The specific aims were:
(1) to identify FH-related mutation(s) in clinically diagnosed FH patients and their at- risk
family members
(2) determine the best age-sex specific lipid/clinical criteria for diagnosing FH in the
South African population
(3) use DNA data to determine what percentage of FH patients could be diagnosed by
clinical criteria
(4) determine the rate at which specific genes for FH are unexpressed in lipid tests
(5) determine whether clinical criteria need to be different by country/population.
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CHAPTER2
MATERIALS AND METHODS
DETAILED EXPERIMENTAL PROCEDURES
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2.1 Isolation of DNA
Four different DNA isolation methods were used during this study.
Method 1: This method was used for the isolation of DNA from whole blood. EDTA-
preserved blood was mixed with 40 ml cold lysis buffer (155 mM NH4GI; 10 mM KHG03;
0.1 mM EDTA with pH 7.4) in a 50 ml polypropylene Falcon tube. The lysis mixture was
placed on ice until lysis of RBS was apparent. Then the mixture was centrifuged at 1500
rpm for 10 minutes. The supernatant was removed with care as not to disturb the pellet.
The cell pellet was washed carefully by gently mixing with 10 ml PBS (dissolve 10
tablets in 1 litre of ddH20, OXOID) buffer. The supernatant was removed and the pellet
resuspended in 3 ml nuclei lysis buffer (10 mM Tris-Cl; 400 mM NaGI; 2 mM EDTA at pH
8.2), 50 III proteinase K (10 mg/ml, Boehringer Mannheim) and 300 III 10% SDS (w/v).
This solution was then mixed on a vortex for 5 seconds and incubated overnight at
The next morning 1ml of saturated 6 M NaGI solution was added to each tube and then
shaken vigorously for approximately 1 minute followed by centrifugation at 2500 rpm 'for
15 minutes. The precipitated pellet was left at the base of the tube and the supernatant
that contains the DNA transferred to a fresh 50 ml Falcon tube. Two volumes of cold
absolute ethanol was added to the tube and left at room temperature for the DNA to
precipitate. The precipitated DNA strands were subsequently removed with a glass
pipette and transferred to a labelled 1.5 ml microcentrifuge tube. Then 70% ethanol was
-,
added to rid the DNA of excess salt followed by centrifugation. Excess ethanol was
Stellenbosch University http://scholar.sun.ac.za
14
removed and the DNA left to air-dry at room temperature. The DNA pellet was then
dissolved in 300-500 ~I of sterile ddH20 (Miller et al., 1988).
Method 2: This method involved the use of DNAzol™ (GibcoBRL). Approximately 200 ~I
whole blood was mixed with 1 mllysis buffer (155 mM NH4CI; 10 mM KHC03; 0.1 mM
EDTA with pH 7.4) and placed on ice until RBC underwent lysis - usually after 10
minutes. The solution was centrifuged in a benchtop centrifuge at 13 000 rpm for 1
minute and the supernatant carefully removed. The pellet was then washed with 1 ml
PBS (Dissolve 10 tablets in 1 litre of ddH20, OXOID) and centrifuged for 30 seconds.
The supernatant was removed and 100-200 ~I DNAzol™ (GibcoBRL) added depending
on pellet size, vortexed and left on the bench for 5 minutes. The preparation was then
centrifuged at 13 000 rpm to remove cell debris. Two volumes of cold 100% absolute
ethanol were added and the solution left at room temperature for DNA to precipitate.
Precipitated DNA strands was removed with a glass pipette and placed in a labelled 1.5
ml microcentrifuge tube containing 70% ethanol. The sample was then centrifuged and
excess ethanol removed. DNA was washed with 1 ml of SABAX water before
centrifugation. The resultant DNA pellet was dissolved in 500 ~I 8 mM NaOH and
buffered with 25 ~I Tris-CI (pH 8.0).
Method 3: This method was employed for the isolation of DNA from buccal swabs and
cultured amniotic cells. Perkin Elmer (CheekSwab) mouth brushes were used to collect
buccal cells in cases where blood samples could not be obtained. The cells were
pelleted by centrifuging for 10 minutes at 2500 rpm. The supernatant was discarded and
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the pellet resuspended in 200 )lI 50 mM NaOH. The mixture was placed in a fresh
microcentrifuge tube. A hole was made in the top of the tube with a hypodermic needle
and boiled for 10 minutes on a floating tray in boiling water. The solution was buffered
with 25 )lI 1 M Tris-CI (pH 8.0). The DNA was then pipette into a fresh tube (Talmud et
al.,1991).
Method 4: This method is a shortened version of the first method. Approximately 400 )lI
freshly prepared 170 mM NH4CI was mixed with 100 ul whole blood and incubated at
room temperature for 20 minutes. By centrifugation for 30 s at 13 000 rpm the white
blood cells were pelleted and the supernatant discarded. The pellet was washed several
times with cold 0.9% NaCI (commercial available saline). After resuspending the pellet in
200 ul 50 mM NaOH the mixture was boiled for 10 minutes on a floating tray in boiling
water. To buffer the solution 25 )lI 1M Tris-CI (pH 8.0) was added. The DNA was then
placed in labelled tubes.
2.2 Determination of DNA concentration
DNA concentration was determined by spectrophotometry. The readings were taken at
UV wavelengths of 260 nm and 280 nm. An OD of 1 at 260 nm corresponds to
approximately 50 !-lg/ml of double stranded DNA. The purity of the sample was
calculated by the ratio of readings at 260 nm and 280 nm (OD260/0D280). Pure DNA
showed a value of 1.8 while a value above 1.8 indicated RNA contamination and a value
below 1.8 protein or phenol contamination. Contaminated DNA samples were subjected
to DNA purification techniques.
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2.3 DNA Purification
Those DNA samples which did not yield a product following PCR amplification, were
subjected to ethanol precipitation and phenol-chloroform purifications.
2.4 Polymerase Chain Reaction (PCR)
Genomic DNA was amplified by the polymerase chain reaction in a Hybaid Omnigene
Thermal Cycler (Hybaid, Teddington, Middlesex, UK) or a Perkin Elmer Thermal Cycler,
PE 9700 (Perkin Elmer, South Africa Pty Ltd., Johannseburg, SA). The PCR primers
used in this study are listed in Tables 2.1 (Jensen et al., 1996) and 2.2 (Nissen et al.,
1996). Each PCR reaction consisted of 20-50 ng genomic DNA, 20 pmol each of
forward and reverse primers, 100 11Mof each dNTP, 10X Buffer with/without 1.5 mM
MgCI2, 25 mM MgCI2 (optional), 0.5 U Taq DNA polymerase, 200 11MCresol red loading
buffer and nuclease-free water to a final volume of either 25 or 50 Ill.
2.5 Multiplex PCR
Three founder-related mutations (D154N, D206E and V408M) causing FH in 90% of
affected Afrikaners (Kotze et al., 1991) were screened with the use of multiplex
amplification refractory mutation system (ARMS-PCR). Three common (COMM 1-3) and
three ARMS primers specific for the mutant alleles of the LDLR gene were used (Kotze
et al., 1995). Reactions included genomic 0.5 Ilg DNA, 2 1) of Taq DNA polymerase
(Boehringer Mannheim), 100 mmoIII Tris-HCI, 15 mmol/I MgCI2, 500 mmoIII KCI with pH
8.3 at 20°C, 200 11Mof each dNTP, 25 pmol of primer COMM 1, 50 pmol of primer
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ARMS 1, 10 pmol of primers COMM 2 and ARMS 2, 100 pmol of primers COMM 3 and
ARMS 3, 2 mM tetramethylammonium chloride and 15% glycerol overlaid with light
mineral oil (Sigma).
Thermal cycling was performed in a Perkin-Elmer Thermal Cycler, PE 9700. The PCR
program included an initial denaturation step of 5 minutes at 94°C, followed by 15 cycles
of denaturation at 94°C for 1 minute, annealing at 62°C for 1 minute and an extension at
72°C for 2 minutes. This was followed by 20 cycles of the same conditions but with an
annealing temperature of 55°C, followed by a final step at 35°C for 10 seconds.
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Table2.1 PrimersusedtoamplifythepromoterandcodingregionoftheLDLR
gene.
Region! Oligonucleotides quence (5'to3')
l
Fragment
Exon size(bp)
PromoterF GAGGCAGAGAGGACAATGGC
R CACGACCTGCTGTGTCCAAGCTTGAAACCC 277
1 F CACATTGAAATGCTGTAAATGACG
R CTATTCTGGCGCCTGGAGCAAGCC 215
2 F TTGAGAGACCCTTTCTCCTTTTCC
R GCAT ATCATGCCCAAAGGGG 183
3 F TTCCTTTGAGTGACAGTTCAA TCC 0,
R GATAGGCTCAATAGCAAAGGCAGG 196
4A F GTGGTCTCGGCCATCCATCC
R AGCCATCTTCGCAGTCGGGG 242
4B F CCCCCAGCTGTGGGCCTGCG
R CGCCCCCACCCTGCCCCGCC 237
5 F AGAAAATCAACACACTCTGTCCTG
R GGAAAACCAGATGGCCAGCG 180
6 F TCCTCCTTCCTCTCTCTGGC
R TCTGCAAGCCGCCTGCACCG 179
7 F GGCGAAGGGATGGGT AGGGG
R GTTGCCATGTCAGGAAGCGC 236
8 F CATTGGGGAAGAGCCTCCCC
R GCCTGCAAGGGGTGAGGCCG 220
9 F CCCCTGACCTCGCTCCCCGG
R GCTGCAGGCAGGGGCGACGC 224
10 F ATGCCCTTCTCTCCTCCTGC
R AGCCCTCAGCGTCGTGGATA 278
11 F TCCTCCCCCGCCCTCCAGCC
R GCTGGGACGGCTGTCCTGCG 194
12 F ACTGGCATCAGCACGTG~CC
R CGTGTGTCTATCCGGCCACC 236
13 F GTCATCTTCCTTGCTGCCTG
R TTCCACAAGGAGGTTTCAAGGTTGGGGGGG 329
14 F AAA TTTCTGGAA TCTTCTGG
R GCAGAGAGAGGCTCAGGAGG 268
15 F AGAAGACGTTTATTTATTCTTTC
R GTGTGGTGGCGGGCCCAGTCTTT 217
16 F CCTTCCTTT AGACCTGGGCC
R CATAGCGGGAGGCTGTGACC 173
17 F GGGTCTCTGGTCTCGGGGGC
R GGCTCTGGCTTTCTAGAGAGGG -, 242
18 F GCCTGTTTCCTGAGTGCTGG
R TCTCAGGAAGGGTTCTGGGC 135
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Table 2.2 Primers used to amplify the promoter and coding region of the LDLR gene
for DGGE.
Regionl Oligonucleotide sequence (5' to 3') Fragment
Exon size (bp)
30% to 70% denaturant gradient
Promoter F 40-bp GC-ciamp-AGGACTGGAGTGGGM TCAGAGC
RTGCTGTCCTAGCTGGAAACCC 252
2 F 40-bp GC-clamp-CGTGGTCAGTITCTGA TICTGGCG
R ATAMTGCATATCATGCCCAMGG 253
3 F 40-bp GC-clamp- TCGGCCTCAGTGGGTCTITC
R ACTCCCCAGGACTCAGATAGGC 268
5 F 40-bp GC-clamp-GGCCCTGCTIGTITITCTCTGG
R AGCAGCMGGCACAGAGAATGG .. 282
6 F 40-bp GC-ciamp-ACGAAACTGAGGCTCAGACACACC
R GCTCCCCACAAACTCTGCAAGC 262
10 F GCAGTGAGATGAGGGCTCCTGG
R 40-bp GC-ciamp-CCTGCAGCCCTCAGCGTCG 349
11 F 40-bp GC-ciamp-GGATCCTCCCCCGCCCTC
R TGGCTGGGACGGCTGTCC 239
12 F GGCCCTCAGGCCCTCTGG
R 40-bp GC-ciamp-CCGAGTTTTCTGCGTICATCTI 336
13 F 50-bp GC-clamp-GTCATCTICCTIGCTGCCTG
R CACMGGAGGTITCAAGGTIGG 264
17 F 50-bp GC-ciamp-GGGCAGCTGTGTGACAGAGCG
R CATGGCTCTGGCTTICTAGAGAGG 279
ApoB F 40-bp GC-clamp-GGAGCAGTIGACCACAAGCTI AGC
R GGTGGCTITGCTIGTATGTTCTCC 382
40% to 80% denaturant gradient
1 F 50-bp GC-clamp- TIGAAA TGCTGT AM TGACGTGG
R CTGGCGCCTGGAGCAAGC 256
4A F 40-bp GC-clamp':ACTGCGGCAGCGTCCCCGGC
R GGATGCAGGTGGAGCTGTIGC 297
4B F ACCTGTGGTCCCGCGAGC
R 40-bp GC-clamr:-CCAGGGACAGGTGAT AGGACG 345
7 F 40-bp GC-ciamp-AGAGTGACCAGTCTGCATCCCTGG
R TTGGTTGCCATGTCAGGAAGC 253
8 F 40-bp GC-clamp- TCCCCACCAAGCCTCTTICTCTC
R CCACCCGCCGCCTTCC 222
9 F 46-bp GC-/1 O-bp AT -clamp-CTGACCTCGCTCCCCGGACC
R GGCTGCAGGCAGGGGCGACG 278
14 F 50-bp GC-clamp- TCTCGTTCCTGCCCTGACTCC
R GACACAGGACGCAGAAACMGG 274
15 F 3-bp GC-clamp-GGCACGTGGCACTCAGMGACG
R 50-bp GC-ciamp-GTGTGGTGGCGGGCCCAGTCTTT 288
16 F 50-bp GC-clamp-CTCCA TTICTIGGTGGCCTICC
R CATAGCGGGAGGCTGTGACCTGG 239
18 F 50-bp GC-clamp-CCTGAGTGCTGGACTGAT AGTTTCC
R AAGGCCGGCGAGGTCTCAGG 190
3-bp GC-clamp: CGG
40-bp GC-clamp: CGCCCGCCGCGCCCCGCGCCCGTCCCGCCGCCCCCGCCCG
46-bp GC-/1 O-bp AT-clamp: CGCCCGCGCCCGCCGCGCCCCGCGCCCGTCCCG
CCGCCCCCGCCCGAMTAATAAA
50-bp GC-clamp: CGCCCGCCGCCGCCCGCCGCGCCCCGCGCCCGTCCCGCC
GCCCCCGCCCG
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2.6 Agarose gel electrophoresis
The PCR products were loaded on a 2% agarose gel, electrophoresed for 30 minutes at
100 V, stained for 5 minutes in 1x TBE containing ethidium bromide (10 mg/ml) and
examined under ultraviolet light.
2.7 Heteroduplex-single strand conformation polymorphism (HEX-SSCP) analysis
HEX-SSCP analysis was performed on a 20 cm vertical gel apparatus. The gel
preparation was as follows: firstly the two glass plates were clamped together with
binder clips and an agarose plug was poured at the bottom. The polyacrylamide (PAA)
gel was poured between the two glass plates, the gel allowed to polymerise (6-10
minutes) and a 1mm comb was inserted between the glass plates. The PCR products
(10-15 ul) were denatured for 5 minutes at 95°C (Kotze et al., 1995) in the presence of
cresol red loading buffer, loaded on the PAA gel and electrophoresed at room
temperature overnight at 100 V in 1X TBE buffer. The following morning the apparatus
was disassembled and the gel stained for 10 minutes in 1X TBE containing ethidium
bromide (10 mg/ml) and then destained in distilled water for 5 minutes. Finally the DNA
was visualised on the UVP Image Store 500 Ultra-Violet transilluminator system, and
photographed with the Sony Video Graphic Printer (UP 860 LE) system.
The buffers used in this study were prepared as describe9 in "Molecular Cloning: A
Laboratory Manual" (Sambrook et al., 1989). The stock solutions for HEX-SSCP
analysis were:
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1. 40% stock (1% C)
39.6 g acrylamide
0.4 g bisacrylamide
Made up to a total volume of 100 ml with ddH20
2. 10% Ammoniumpersulphate (APS)
2 g Ammoniumpersulphate
20 ml ddH20
3. Loading buffer
Formamide Blue (25 ml): 95% formamide (de-ionised) 22.7 ml, 20mM EDTA
(disodiumsalt) 0.168 g, 0.05% Xylene Cyanol 0.0125 g, 0.05% Bromophenol blue
0.0125 g.
Ficoll Orange G (100 ml): 0.1% Orange G 0.1 g, 20% Ficoll20 g, 10 mM EDTA 0.29 g.
Cresolred: 1 mmoiII Cresolred 3.82 g, 60% Sucrose 60 g.
Three different PAA gel systems were used:
System 1. 10% Urea gel (combined heteroduplex and SSCP)
1.5X TBE final buffer concentration
4.5 g Urea
18 ml 5X TBE
26 ml ddH20
15 ml of 40% stock solution (1% C)
800 !lI APS (10% stock)
80!l1 TEMED
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System 2. 5% Glycerol gel
0.5X TBE final buffer concentration
3 ml glycerol
6 ml5X TBE
36 ml ddH20
15 ml of 40% stock (1% C)
800 ~I APS (10% stock)
80 ~I TEMED
System 3. 20% Mighty Small
0.5X TBE final buffer concentration
1 ml5X TBE
4 ml ddH20
5 ml of 40% stock (1% C)
80 ~I APS (10% stock)
40 ~I TEMED
2.8 Denaturing gradient gel electrophorese (DGGE)
Two different denaturant concentrations (30-70% and a 40-80%) were used to prepare
the gels. Two glass plates with 1mm spacers were clamped together with binder clips. A
gradient mixer was put above the DGGE frame. Exactly 14 ml of the lower denaturant
concentration was poured in the left side and 14 ml of the higher concentration in the
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right chamber of the gradient mixer. The connection between the two chambers was
opened to let the solution passes through the plastic tube between the two glass plates.
The gel was then allowed to polymerise for an hour. After one hour, the gel apparatus
was placed into the bath containing 1X TAE buffer heated to 60°C and then loaded 7.5-
10 J.l1 PCR product on the gel. Electrophoresis was performed for 5 hours at 150 V or
overnight at 50 V at a constant temperature of 60°C. Staining of the gel was done in 1X
TAE buffer containing ethidium bromide (10 mg/ml) for 10 minutes, destained in distilled
water for 5 minutes. Then visualised on the UVP Image Store 5000 Ultra-Violet
transilluminator system and photographed with the Sony Video Graphic Printer (UP 860
LE) system.
2.9 Restriction enzyme analysis
A reaction for restriction enzyme digestion was prepared by adding the following
reagents to a microcentrifuge tube: PCR product (1-10 J.l1, >40 ng), 10X enzyme specific
buffer (1/1Oth volume), restriction enzyme (1-10 units per 10 J.l1 PCR product) and filled
up as appropriate with sterile distilled water. The solution was gently mixed by pipetting
and the reaction incubated at the specified temperature (usually 3rC) for at least 1
hour, but preferably overnight. The enzyme was inactivated by heating at 70-100°C for
10 minutes (see instructions for specific enzymes). Then 5 J.l1 of loading buffer was
added and the product loaded on a PM gel.
The stock solutions for restriction enzyme analysis were:
30% stock (3.4% C)
58.8g acrylamide
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1.2g bisacrylamide
Make up to a total volume of 200 ml with dH20.
2.10 Sequencing
Automated sequencing was performed when aberrations were detected. For automated
sequencing, the Perkin Elmer 310 sequencer was used.
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Abstract
Objective. Familial hypercholesterolaemia (FH) is a common genetic disease
characterised by strikingly elevated plasma cholesterol concentration, which can lead to
premature coronary death if left untreated. In this study DNA diagnosis of FH, which
allows detection before onset of clinical symptoms, was evaluated against biochemical
parameters routinely used to identify subjects with FH.
Design. A population-based strategy was used to identify low-density lipoprotein
receptor (LDLR) gene defects in South Africans with clinical signs of FH, followed by a
family-based DNA screening approach for presymptomatic diagnosis of FH.
Results. The systematic molecular analysis of FH resulted in the identification of at
least ten founder-type LDLR gene mutations among the 65 different gene defects
described to date in the diverse South African population. DNA screening of 790 at-risk
family members for the FH-related mutations identified in 379 index cases, allowed
accurate disease diagnosis in an additional 338 relatives and exclusion of the relevant
mutation in 452 individuals. The sensitivity and specificity of the diagnosis, based on
total cholesterol values measured in family members of index cases recruited for this
study, were 89.3% and 81.9%, respectively.
Conclusions. The predominance of at least ten LDLR gene mutations in the local
population justifies population-directed DNA diagnosis of FH in South Africa on a routine
basis, particularly since expression of the defective gene measured in biochemical tests
does not allow accurate diagnosis of FH in all cases. DNA testing provide a definitive
tool for family tracing aimed at pre-clinical diagnosis and preventive treatment of FH.
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INTRODUCTION
The diagnosis of familial hypercholesterolaemia (FH) is based on clinical findings and
elevated low-density lipoprotein (LOL) cholesterol levels. The rare homozygous form of
the disease is characterised by severe clinical features, including tendon xanthomas and
atherosclerosis, usually associated with early coronary death during childhood. Most FH
heterozygotes carrying one defective low-density lipoprotein receptor (LDLR) gene do
not present with cholesterol deposits in the skin and tendons, which complicates disease
diagnosis and consequently preventive treatment (Goldstein et al., 1995). DNA analysis
may therefore be more appropriate for the diagnosis of heterozygous FH, particularly in
homogeneous populations where a limited number of LDLR gene mutations account for
the disease in the majority of cases.
The diverse South African population provides a valuable source of material for genetic
studies. Initial studies focussed on the Afrikaner population, considered to be a genetic
isolate due to its unique geographic and historical situation. The predominance of
specific disease-associated chromosomes in this population group (Kotze et al., 1987;
1989a) confirmed the occurrence of a founder effect (Seftel et al., 1980), and led to the
identification of three mutations that are responsible for the disease in approximately
90% of Afrikaner FH patients (Leitersdorf et al., 1989; Kotze et al., 1989b; 1990). The
value of a routinely used DNA-based test was demonstrated (Kotze et al., 1992; 1994),
"
necessitating the development of a cost-effective method to screen for multiple
mutations in a single reaction (Kotze et al., 1995b). Population screening by direct
detection of the founder mutations D154N, D206E and V408M, confirmed the high
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prevalence of heterozygous FH (1/70) in Afrikaners (Steyn et al., 1996). Loubser et al.
(1999) demonstrated that these mutations are also responsible for the disease in up to
15% of South African FH patients of mixed ancestry (Coloured population). This finding,
as well as frequent detection of two LDLR gene mutations causing FH in the majority of
South African jews (del 3-bp) (Meiner et al., 1991) and Indians (P664L) (Rubinsztein et
al., 1992; Kotze et al., 1997), provided direct genetic evidence that Caucasoid admixture
contributes significantly to the FH phenotype in South Africans of mixed ancestry. A 6-bp
deletion identified in a Xhosa with homozygous FH appeared to be absent in the
Coloured population (Leitersdorf et al., 1988). Frequent detection of this deletion-
mutation in FH patients from the South African Black population (Thiart et al., in press),
where this disease appears to be extremely rare, suggests that FH may be
underdiagnosed in this group. This finding supports the notion that clinical criteria for the
diagnosis of FH need to be different by country/population (Primstone et al., 1998).
DNA screening for FH should be a priority in South Africa, where specific founder-type
mutations contribute significantly to the high death rate from coronary heart disease
(CHO) in several population groups. However, FH is largely underdiagnosed locally,
such that most of the affected individuals are not treated to prevent unnecessary early
deaths due to heart attacks. Studies are ongoing to identify the disease-causing
mutation in patients being referred for molecular diagnosis, but family follow-up is rarely
performed, partly due to costs involved. This is an unfortunate situation, since tracing of
-,
defective LDLR genes in families would enable accurate diagnosis of FH or exclusion of
the disease in at-risk family members. Most importantly, it would identify those family
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members at high risk of developing CHO, so that cholesterol levels can be lowered or
normalised by dietary and/or drug treatment.
In an attempt to identify and assist families with FH, an international project aimed at
"Making Early Diagnosis to Prevent Early Deaths in MEDical PEDigrees" (MED-PED)
was initiated, which currently involves more than 30 countries worldwide. In a report by
Williams et al. (1993) on this family-based case-finding approach, it was suggested that
more rigid cholesterol screening should be used for persons in the general population
whose chance before cholesterol testing may be only 1 in 500 (1 in 70 in Afrikaners), in
contrast to first-degree relatives of a confirmed FH case whose chance before
cholesterol testing is 50%. In this study the MED-PED approach was followed to screen
family members of molecularly-characterised FH index patients for known mutations in
the LDLR gene. In order to extend the spectrum of LDLR gene mutations, clinically
diagnosed FH index cases without known mutations were subjected to extensive
screening of the promoter and coding region of the LDLR gene. The objectives of the
study were to (i) determine what percentage of FH patients could be diagnosed by
clinical criteria and (ii) determine the rate at which specific genes for FH are
unexpressed in lipid tests.
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MATERIALS AND METHODS
Subjects
Patients were selected for mutation screening using previously-described clinical criteria
for a diagnosis of FH (Kotze et al., 1987). Pretreatment total serum cholesterol (TC)
levels had to be at least equal to the so" percentile for age and gender (Rossouwet al.,
1985), with normal serum triglyceride (TG) levels «2.3 mmol/I). In addition, a FH study
participant had to have either clinical features of FH (tendon xanthoma of the Achilles
tendon or tendons on the dorsum of the hand with or without xanthelasma) or a family
history of early CHO. Family follow-up was performed/extended in families where the
FH-related mutation has been identified in the index case, while index cases without
known mutations were subjected to extensive mutation screening and/or family follow-
up. Known mutations causing familial defective apolipoprotein B-100 (FOB) (Soria et al.,
1989) were excluded in all the study participants using previously-described methods
(Kotze et al., 1994; Jensen et al., 1996).
The study protocol was approved by the Ethics Review Committee of the University of
Stellenbosch and all blood samples were obtained with informed consent. In this study
"White" or "Afrikaner" refers to an individual of European descent, mainly Dutch, French,
German and British stock; "Coloured" refers to an individual of mixed ancestry, including
San, Khoi, African Negro, Madagascar, Javanese and Western European origin; "Black"
<,
refers to South Africans of central African descent.
Stellenbosch University http://scholar.sun.ac.za
33
Methods
Genomic DNA was extracted from whole blood collected in EDTA-containing tubes,
according to a standard technique (Miller et al., 1987). PCR amplification of the coding
region of the LDLR gene was performed using the exon-specific primers described by
Jensen et al. (1996), or allele-specific primers specially designed for detection of
mutations known to be common in South Africa (Kotze et al., 1995b). The promoter
region of the LDLR gene was amplified using primers 5'-
GAGGCAGAGAGGACAA TGGC-3' and 5'-CCACGTCA TIT ACAGCA TTTCAA TG-3'.
Heteroduplex-single strand conformation polymorphism (HEX-SSCP) analysis was
performed using three different gel systems to improve mutation detection efficiency:
10% (1%C) polyacrylamide gel supplemented with 7.5% urea; 10% (1%C)
polyacrylamide gel supplemented with 5% glycerol and 20% (1%C) polyacrylamide gel.
Electrophoresis was carried out overnight at room temperature and at 4°C on a 20 cm
Hoeffer gel apparatus. When no aberrant patterns could be detected with the HEX-
SSCP method, denaturing gradient gel electrophoresis (DGGE) was performed as
described by Nissen et al. (1996). PCR products showing aberrant patterns were
sequenced with the automated ABI 373 system. Where appropriate, restriction enzyme
analysis was performed for confirmation, to screen for known mutations, and to trace
specific mutations in families.
Evaluation of biochemical versus DNA diagnosis was performed in families with the
-,
Afrikaner founder mutations D206E (FH 1), V408M (FH2) or D154N (FH3), of which the
deleterious effects have previously been confirmed at the cellular level (Fourie et al.,
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1988; Graadt van Roggen et aI., 1995). Since index patients had been selected on the
basis of elevated TC levels, genotype/phenotype correlations were only performed in
family members recruited through tracing of defective genes in the pedigrees.
RESULTS
The spectrum of mutations in the diverse South African population, including four novel
mutations detected for the first time during the course of this study, are summerised in
Table 1. Sixty-five different disease-related mutations were identified in 379 index
patients. Of the 790 at-risk relatives analysed, 338 inherited the disease-related LDLR
gene mutation.
Table 1. Spectrum of mutations identified in the LDLR gene in different South African
I fpopu a Ion groups
Exon/ Molecular Event Designation No. Relatives References
Intron Tested
AFRIKANER POPULATION
Exon 3 T~G at 259 W66G 1 None Leitersdorf et al., 1990
Exon 4 G~A at 523 D154N 31 55 +,105- Kotze et al., 1989b
Exon 4 A~G at 662 D200G 5 3 +, 1 - Hobbs et al., 1992
Exon 4 Ins 18-bp after 681 Ins AA 201-206 1 1 +, 5- Kotze et al., 1995a
Exon 4 C~G at 681 D206E 144 144 +,194- Kotze et al., 1990
Exon 6 C~Tat917 S285L 3 2 +, 2- Hobbs et al., 1992
Exon 7 C~T at 1048 R329X 1 None Solberg et al., 1994
Exon 8 G~A at 1130 C356Y 4 5 +, 1 - This study
Exon 8 G~T at 1145 G361V 2 3 +, 4- This study
Exon 9 G~A at 1285 V408M 57 51 +,61 - Kotze et al., 1989b
Exon 16 G~A at 2389 V776M 1 None Pereira et al., 1995
MIXED ANCESTRY (COLOURED POPULATION)
Promoter C~T at -59 -59c~t 1 3 +, 14 - Scholtz et al., 1999
Exon 1 T~C at 28 W-12R 1 None Marx et al., 1997
Exon 2 G~A at 148 A29T 1 None Loubseretal.,1999
Exon 3 C~T at 232 R57C 1 None Day et al., 1997
Exon 3 C~T at 241 R60C 1 None Nissen et al., 1998
Exon 4 del TC after 368 del2-bp 1 None Loubseretal.,1999
Exon 4 G~A at 523 D154N 2 None Kotze et al., 1989b
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Exon 4 del G at 617 617 del G 1 None Callis et aL, 1998
Exon 4 C~ G at 6815 D206E 1 None Kotze et al., 1990
Exon 6 G~A at 910 D283N 1 None Bilheimer et al., 1985
Exon 7 C~T at 1048 R329X 1 None Solberg et al., 1994
Exon 8 A~C at 1133 0357P 1 None Callis et al., 1998
Exon 8 C~T at 1150 0363X 1 3 +, 4- Kotze et al., 1997
Exon 8 C~G at 1156 D365E 1 3 +, 4- Kotze et al., 1997
Exon 9 G~C at 1329 W422C 1 None Hobbs et al., 1992
Exon 10 Com_Qlexdel/ins 16-bp del/5-bp ins 1 None This study
Exon 10 T~C at 1447 W462R 1 None Ward et al., 1995
Exon 11 G~A at 1646 G528D 1 2+ Hobbs et al., 1992
Exon 11 A~C at 1690 N543H 1 None Tricot-Guerber et al., 1995
Exon 14 C~A at 2043 C660X 2 7 +, 2- Lehrman et al., 1987
Exon 14 del T at 2092 2092 del T 1 4 +,1 - Hobbs et al., 1992
Intron 14 G~A at 2140+5 2140+5G~A 1 None Heath et al., 1999
Exon 17 del 9-bp after 2393 2393 del 9-bp 1 None Lombardi et al., 1996
The majority of mutations summerised in this table were included in a recent mutation
update (Varret et al., 1998).
Table 2 shows the characteristics of 11 hypercholesterolaemics diagnosed with FH on
the basis of clinical features, but in whom no mutations could be identified despite
extensive analysis of the LOLR and apo B genes.
Table 2. Characteristics of 11 molecularly-uncharacterised patients diagnosed with FH
on the basis of clinical and biochemical features
Index Sex Age LDLC Clinical Origin
RM f 54 9.3 Arc, Xan Black
AM f 58 5.7 Arc, Xan European
CN f 58 5.3 Arc Black
CK m 26 12.1 Arc, Xan Black
LM f 56 3.5 Arc, CHO Afrikaner
TM m 53 5.0 Arc, MI Black
PL m 36 7.5 Arc, Xan, CHO Indian
ST f 62 6.1 Arc European
lG f 54 5.1 Xan Afrikaner
AM f 70 6.3 Arc, Xan Black
JO f 64 4.7 Arc, Xan European
LOLC, low-density lipoprotein cholesterol; CHO, coronary heart disease; Arc, arcus
cornealis; Xan, xanthomata; MI, myocardial infarction.
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Mutations 0200G (exon 4), S285L (exon 6), C356Y (exon 8) and G361V (exon 8) were
identified in 14 unrelated Afrikaner families without the previously described founder
mutations. The pedigrees of four of these families are illustrated in Figure 1, together
with the results obtained after HEX-SSCP and restriction enzyme analysis. Mutation
0200G in exon 4 creates a Mspl restriction enzyme recognition site, and after digestion
three bands of 237-bp (normal allele), 176-bp and 61-bp (mutant allele) are observed in
heterozygous individuals. Mutation C356Y in exon 8 creates a Rsal restriction enzyme
recognition site and after digestion three bands of 220-bp (normal allele), 115-bp and
105-bp (mutant allele) were observed in FH heterozygotes.
Figure 1. Identification of mutations 0200G, S285L, C356Y and G361V in 4 Afrikaner
families. Mutation-positive family members are indicated in dark-shaded symbols.
(A )Pedigree structures with ages and lipid profiles indicated (TC, Total cholesterol;
HOL, High density lipoprotein cholesterol; TG, Triglyceride; LOL, Low density lipoprotein
cholesterol). (8) Oetection of mutations in the LOLR gene using HEX-SSCP and
restriction enzyme analysis. Lane 1 and 2 represent mutation positive and control cases,
respectively [see next page].
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Family no. 129
Mutation D200G
A
1/
1/1
Age
TCHOL
TGLOL
52 13 25 23 50 21 47 13 9 41
89 4.1 4.8 5.1 4.1 5.0 9.8 6.5 7.5 5.2
1.1 1.1 09 1.2 1 9 1.7 1.1 1.4 1.6 1.3
1 9 1.3 1.3 2.0 22 1.6 1.7 1.1 1.0 1.9
6.9 24 3.3 3.0 1.2 2.6 7.9 4.6 5.4 3.0
Family no. 186
Mutation C356Y
Family no. 943
Mutation S285L
[I ()
2
6 J [5~}
2 3 4
Age 45 1ï 11 9 43TC 8.4 4.7 6.9 4.9 7.1HOL 1.2 1.6 1.1 1.6 1.8TG 1.6 0.6 1.2 09 0.6LOL 6.5 2.8 5.2 29 5.0
Family no. 262
Mutation G361V
II
III
III
Age 58 31 43 22 12 40
TC 96 9.5 96 10.0 9.9 6.1 5.5HOL 1.0 1.6 2.2 1.2 1.5 1.2 1.5 Age 44 41 9 5 37 68 38 34 33
TG 1.5 1.6 2.7 0.9 1.6 1.4 1.1 TC 9.5 7.5 7.7 7.2 7.4 9.6 9.2
5.0 6.3
LOL 7.9 7.2 6.2 8.4 7.7 4.3 3.5 HOL 0.9 0.8 0.9 1.1 0.9 0.6 0.8 1.0 0.8TG 59 1.3 1.2 0.8 2.1 3.6 3.2 1.9 5.3LOL 5.9 6.1 6.3 5.7 5.5 7.3 6.9 3.1 3.1
B
0200G S285L
1 2 1 2
~
MspI
- 237bp
220bp
115bp
105bp
C356Y G361V
1 2 1 2
-J
RsaI
- 220bp
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In Table 3, 448 at-risk family members (>18 years old) screened for one of the three
Afrikaner founder mutations previously identified in the index case were grouped
according to the presence of TC levels above the ao" and 95th percentile for age and
gender. Evaluation of biochemical versus DNA diagnosis revealed that 11.8% may be
misdiagnosed when the so" percentile is used as a biochemical cut-off point for a
diagnosis of FH, compared to 29.4% using the 95th percentile for age and gender
(Rossouwet al., 1985). In total, 18/153 relatives with a FH mutation were falsely
classified as normal (negative predictive value of 88%), whilst 68/296 without the
mutation were falsely classified as FH heterozygotes (positive predictive value of 77%).
The sensitivity and specificity of FH diagnosis according to TC values (80th percentile)
were therefore 88% and 77%, respectively.
Table 3. Evaluation of biochemical versus DNA diagnosis in family members of Afrikaner
index patients (>18 years) with disease-causing LOLR gene mutations.
Mutation Number of >95tn percentile >80tn percentile
relatives
0206E 94 62 (65%) 83 (88%)
V408M 28 21 (75%) 24 (86%)
0154N 30 25 (83%) 29 (97%)
No mutation 296 13 (4%) 55 (19%)
Total 448
In Figure 2 total cholesterol (TC) concentrations are shown as a function of age in 349
women (A) and 316 men (8) older than 18 years. There is a small overlap in TC levels
between normal and affected individuals. For FH women and men, average TC
concentrations were 7.98 (80=2.49) and 7.61 (80=2.30) mmol/I, respectively.
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In Table 3, 443 at-risk family members (>18 years old) screened for one of the three
Afrikaner founder mutations previously identified in the index case were grouped
according to the presence of TC levels above the 80th and ss" percentile for age and
gender. Evaluation of biochemical parameters revealed that 15.6% may be
misdiagnosed when the eo" percentile is used as a biochemical cut-off point for a
diagnosis of FH, compared to 12.4% using the ss" percentile for age and gender
(Rossouwet aI., 1985). In total, 16/150 relatives with a FH mutation were falsely
classified as normal (negative predictive value of 89.3%), whilst 53/293 without the
mutation were falsely classified as FH heterozygotes (positive predictive value of
81.9%). The sensitivity and specificity of FH diagnosis according to TC values rso"
percentile) were therefore 89.3% and 81.9%, respectively.
Table 3. Evaluation of biochemical versus DNA diagnosis in family members of Afrikaner
ations.index patients (>18 years) with disease-causlnc LDLR qene mut
Mutation Number of >95tn percentile >80th percentile
relatives
D206E 93 61 (66%) 82 (88%)
V408M 27 20 (74%) 23 (85%)
D154N 30 25 (83%) 29 (97%)
No mutation 293 12 (4%) 53 (18%)
Total 443
In Figure 2 total cholesterol (TC) concentrations are shown as a function of age in 349
women (A) and 316 men (B) older than 18 years. There is a small overlap in TC levels
between normal and affected individuals. For FH women and men, average TC
concentrations were 7.98 (8D=2.49) and 7.61 (8D=2.30) mmol/I, respectively.
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Figure 2. Total cholesterol (TC) concentrations as a function of age in 349 women (A)
and 316 men (8).
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DISCUSSION
The mutational spectrum underlying lipid abnormalities differs among population groups.
Knowledge of the exact gene defects causing primary hypercholesterolaemia in a
specific population or family allows accurate disease diagnosis and preventive
treatment. The presence of at least ten founder-type LDLR gene mutations in the South
African population (highlighted in Table 1) enhances the prospects of DNA-based
diagnosis of FH in this country. After exclusion of the three previously-described
Afrikaner founder mutations (D206E, V408M and D154N) a further eight mutations were
identified in this population group (Table 1). Haplotype studies indicated that four of
these mutations (D200G, S285L, C356Y and G361V) detected in 12 Afrikaner families
may represent minor founder mutations (Thiart, 2000).
Mutations C356Y and G361V have not previously been described in other population
groups. Both involve evolutionary conserved residues (Mehta et al., 1991) and occur in
the epidermal growth factor (EGF) precursor homology domain of the LDLR gene that is
responsible for recycling. Evidence in favour of the causitive nature of the two exon 8
mutations furthermore includes the finding that both co-segregate with elevated
cholesterol levels in the families with these mutations, and failure to identify additional
potential gene defects in the remaining part of the LDLR gene. The exon 8 mutations
were also absent in more than 100 normal chromosomes screened. Mutations D200G
and S285L, previously described in European populations from which Afrikaners
originated, resides in the important ligand-binding region of the LDLR gene (Hobbs et
al., 1992; Schuster et al., 1995). In pedigree number 943 (Figure 1), both parents were
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heterozygous for mutation S285L. One of their children died at the age of 6 years of a
heart attack, which most likely was caused by the inheritance of two copies of mutation
S285L. Subject 11-2shown to be heterozygous for mutation S285L, presented with TC
above the zo" percentile for age and gender. One of the mutation-negative children (11-
3) had a TC concentration above the eo" percentile, which might have been falsely
classified as heterozygous FH in the absence of the DNA test. This was in accordance
with the data previously reported by Kotze et al. (1998) who found that a value of 6
mmoiii may best discriminate between mutation-positive and -negative children within
Afrikaner FH families.
In this study the evaluation of biochemical versus DNA diagnosis, previously performed
in 220 children between the ages of 2-18 years (Kotze et al., 1998), were extended in an
Afrikaner adult group including 443 close relatives of 232 index patients with one of the
common founder mutations D154N, D206E or V408M. Although the majority of
mutation-positive cases (>90%) were identified for the first time during mutation
screening, the relative low sensitivity value of 89.3%, compared to that of 93% in the
children sample, could be attributed to some of the patients being on medication. The
specificity value also differed between the adult (81.9%) and children (89%) studies,
which demonstrated that TC levels as a diagnostic means are even less accurate in the
adult population. DNA tests are therefore the preferred method, particularly in
populations where specific mutations predominate.
Separate evaluation of the Afrikaner founder mutations versus TC levels (>80th
percentile) suggests that the penetrance of mutation D154N is the highest of the three
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Afrikaner founder mutations. The estimated sensitivity of detecting this receptor-
defective mutation (Graadt van Roggen et aI., 1995) using biochemical parameters was
97%, compared to 88% for mutation 0206E and 85% for mutation V408M. The finding
that mutation V408M, previously shown to result in less than 2% of receptor activity
(receptor-negative) is biochemically expressed to a lesser or equal degree than
mutations 0154N and 0206E (receptor-defective, 20% activity), may be due to the small
number of relatives analysed for mutation V408M. Notably, one of the male patients with
mutation V408M revealed a normal TC value. This finding provides us with another
example of the extent of clinical variability in FH (Kotze et aI., 1993a; b). The normal TC
value in this V408M heterozygote could be due to interaction with a cholesterol lowering
gene(s) as previously suggested by Hobbs et al. (1989). Ekstrom et al. (1999) have also
described a pathogenic mutation (C240F) in a clinically normal 17-year old subject. Sass
et al. (1995) hypothesised that the apo E2 allele of the apolipoprotein E polymorphism
may be a potent cholesterol-lowering gene. The likelihood of apo E allelic status as a
contributing factor has been excluded in the South African normocholesterolaemic
subject with mutation V408M, since this patient was homozygous for the neutral E3
allele (unpublished data). The genetically homogeneous Afrikaner population provides a
valuable source of material for gene-gene interaction studies and is increasingly used
for this purpose (Lingenhel et aI., 1998).
Failure to identify FH- or FOB-related mutations in 11 clinically diagnosed FH patients
included in this study may be considered a reflection of locus heterogeneity in
autosomal dominant hypercholesterolaemia (AOH). Recently, a novel locus for AOH was
mapped on human chromosome 1 (Varret et aI., 1999). Studies are underway to identify
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and characterise the causative gene, since this may lead to the development of novel
therapeutic strategies targeted at the cause of the disease in a subset of
hypercholesterolaemic families without mutations in the LDLR or apolipoprotein B
genes. Mutation detection could also be compromised by the limitations imposed by the
mutation detection methods used, since the HEX-SSCP and DGGE screening methods
used cannot identify large gene rearrangements.
Approximately half of the offspring of an affected parent can be expected to have a
severely elevated plasma cholesterol level from birth onwards, as was demonstrated in
the children (Kotze et al., 1998) and adult samples. Cardiovascular disease usually
becomes manifested in male and female patients with FH before 55 years of age
(Goldstein et al., 1995), which appear to correspond with data in the Afrikaner
population (Kotze et al., 1993c; Steyn et aL, 1996). However in the Black population
none of the FH heterozygotes with the relatively severe 6-bp deletion in exon 2
presented with CHD (Thiart et al., in press).
This study demonstrated that FH has a very high penetrance in populations of European
descent, which justifies a genetic diagnosis of this treatable disease. The main
advantage of DNA diagnostics is its very high specificity compared to clinical criteria.
The value of the family-based MED-PED screening approach is that identification and
treatment of FH is assured early in life. It also provides t~e opportunity for genetic
counseling to inform families of the importance of mutation screening in other relatives.
Extension of this approach to the population at large would allow more FH patients to be
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diagnosed and subsequently treated by their clinicians, or referred to lipid clinics where
they can receive the intensive care their condition justifies.
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Objective. In this report on the outcome of the first prenatal diagnosis performed for
familial hypercholesterolaemia (FH) in a South African family, we aim to demonstrate the
value of a population-directed screening strategy to identify FH patients in the South
African population, where enrichment of particular gene mutations has significantly
increased the disease prevalence.
Design. Prenatal diagnosis was offered to an Afrikaner heterozygous FH couple who
has two affected daughters, of whom the youngest is severely affected due to the
inheritance of two defective genes. Genomic DNA isolated from amniotic fluid and
peripheral blood of the parents were amplified by the polymerase chain reaction (peR)
and subjected to mutation analysis.
Results. The carrier status of mutation D206E was confirmed in the parents, whilst this
mutation was not detected in DNA directly amplified from amniotic fluid. To exclude the
possibility of a false-negative result due to the limited number of cells in the uncultured
amniotic fluid sample, an aliquot of liquor was also cultured in vitro, and the DNA
extracted and subjected to a second round of analysis. This confirmed the absence of
mutation D206E in the foetus.
Conclusions. This case illustrates the application of a DNA-based mutation detection
technique as a simple and rapid diagnostic aid that can be carried out at a relatively
early gestational stage. Prenatal diagnosis of FH, aimed at the detection of homozygous
cases, is particularly feasible in populations and families with molecularly defined LDLR
gene mutations.
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INTRODUCTION
Familial hypercholesterolaemia (FH) is an autosomal co-dominant disease caused by
mutations in the low density lipoprotein receptor (LDLR) gene. Characteristic features
include elevated levels of low density lipoprotein (LDL), the major cholesterol-transport
lipoprotein in human plasma, and deposition of LDL-derived cholesterol in tendons, skin
(xanthomas) and arteries (atheromas). The world prevalence of heterozygous FH is
approximately 1:500 whilst that of homozygotes is estimated at approximately
1:1000000. The heterozygous form is associated with a high risk of myocardial infarction
usually during the fourth or fifth decade of life, while the rare homozygous condition is
characterised by early atherosclerosis, often resulting in myocardial infarction before the
age of 20 years (Goldstein et al., 1995).
FH heterozygous parents have a 1:4 risk of having a homozygous child. In a relatively
homogeneous population group such as the South African Afrikaner, where the
prevalence of FH has been increased to approximately 1/70 due to a founder effect
(Steyn et aI., 1996), the likelihood of unions which could result in FH homozygous
offspring is significantly increased (Seftel et aI., 1980). Consequently, prenatal diagnosis
of FH is particularly feasible in this population, where three LDLR gene mutations
(D154N, D206E and V408M) are responsible for the disease in approximately 90% of
affected individuals (Leitersdorf et al., 1989; Kotze et al., 1989, 1991). The significance
-;
of DNA screening in populations with a high prevalence of FH due to a founder effect
and/or a high rate of consanguinity has previously been demonstrated by prenatal
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diagnosis performed in a Christian-Arab family with a disease-causing point mutation in
exon 14 of the LDLR gene (Reshef et al., 1992).
The first documented prenatal diagnosis of FH was reported in 1978 and involved the
use of functional assays for quantitative assessment of LDLR activity in cultured
amniotic fluid cells (Brown et al., 1978). This laborious procedure was only applicable to
FH homozygotes with so-called receptor-negative mutations « 2% of activity), since the
technique could not reliably discriminate between homozygotes with detectable receptor
activity and heterozygotes. Measurement of the cholesterol concentration in a foetal
blood sample obtained at the twenty-fourth week of gestation, demonstrating a total
cholesterol concentration of 543 mg/dl compared with the mean value of 66 mg/dl in 48
control foetuses, was subsequently reported by deGennes et al. (1985). The diagnosis
of homozygous FH was confirmed by analysis of foetal skin fibroblasts obtained at the
time of termination. Indirect molecular-genetic approaches using intragenie restriction
fragment length polymorph isms (RFLPs) (Coviello et al., 1993) and microsatellite
markers flanking the LDLR gene (De Oliveira et al., 1998), may be applicable in families
where the disease-causing mutation is uncharacterised. In this study we report the
exclusion of FH in a foetus, using direct mutation detection in an Afrikaner family with
the founder-related LDLR gene mutation D206E. The value of the population-directed
mutation screening strategy used in South Africa, under the auspices of the international
MED-PED (Make Early Diagnosis to Prevent Early Deathst initiative (Will Iiams et al.,
1993), is demonstrated.
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SUBJECTS AND METHODS
Subjects
Prenatal diagnosis was requested by an Afrikaner FH heterozygous couple whose first
child is a FH heterozygote and the second, clinically homozygous (Figure 1). Cutaneous
xanthomas were evident at the age of one year and eight months in the homozygous
child, whose total cholesterol (TC) concentration was 18 mmol/I at the time. The first TC
value measured in this child at the age of two months was reported to be approximately
9 mmol/1. The disease-causing LDLR gene mutation D206E has previously been
identified in both parents and the clinical FH homozygote. Parental bloods and an
amniotic fluid sample were obtained with informed consent.
DNA analysis
Genomic DNA was extracted from whole blood obtained from both parents and directly
from amniotic fluid using a standard technique (Miller et al., 1988). An aliquot of the
foetal sample was also grown to confluency in DMEM medium at 3rC (5% CO2) and
the DNA extracted. DNA was amplified using the polymerase chain reaction (PCR)
technique (Saiki et al., 1988). Multiplex PCR using three sets of allele-specific primers
was performed to simultaneously screen for three founder-related LDLR gene mutations
(Kotze et al., 1995) in order to confirm the presence of mutation D206E in both parents
and determine the disease status in the foetus. Each reactio~ was performed in a total
volume of 50 !-II containing the PCR primers, 0.5 IJg genomic DNA, 2 U Taq DNA
polymerase (Boehringer Mannheim), PCR buffer with MgCI2 (Boehringer Mannheim),
200 IJM each dATP, dCTP, dGTP and dDP, 2 mM tetramethylammonium chloride
Stellenbosch University http://scholar.sun.ac.za
63
(Me4NCI), and 15% glycerol. The PCR program included an initial denaturation at 94°C
for 5 min and then two consecutive amplification steps (1) 15 cycles at 94°C for 1 min,
62°C for 1 min, 72°C for 2 min; and (2) 20 cycles at 94°C for 1 min, 55°C for 1 min, 72°C
for 2 min. Aliquots of the amplified DNA were resolved by electrophoresis on a 10%
polyacrylamide gel. In order to verify the results obtained by the allele-specific PCR,
Ode I digestion of amplified DNA (5-101-11aliquots) was also performed (Kotze et al.,
1991). Primers CCCCCAGCTGTGGGCC and CCGCCCCGTCCCACCCCCGC were
used to amplify exon 4 according to Jensen at al. (1996). Approximately 10 1-11of loading
dye (95% formamide, 20 mM EDTA, 0.05% xylene cyanol, 0.05% bromophenol blue)
was added to the reaction and the resulting products resolved on a 10% polyacrylamide
gel (in 0.5x TBE buffer) for 1% hours at 250V. The gel was stained in ethidium bromide
(10 mg/ml) for 10 minutes, destained in distilled water for another 10 minutes, and
photographed on an UV transilluminator.
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RESULTS
The pedigree of the family is illustrated in Figure 1A. TC levels determined
approximately three years ago in family members were compatible with heterozygous (1-
1, 1-2, 11-1)or homozygous (11-2)FH, as previously reported following the identification of
mutation D206E in this family. The multiplex PCR confirmed heterozygosity for mutation
D206E in both parental samples, while the mutation-specific 285-bp band was absent in
DNA of the foetus (Figure 1B). Since mutation D206E creates a Ode I restriction enzyme
recognition site, absence of mutation D206E was also confirmed by restriction enzyme
analysis (Figure 1C) of foetal DNA samples extracted from both uncultured amniotic fluid
sample and the cultured amniocytes. This finding also excluded the possibility that the
absence of the 285-bp PCR fragment in the foetal sample could have been due to
inadequate DNA.
Figure 1. DNA screening for mutation D206E in a family who requested prenatal
diagnosis of FH. (A) Pedigree structure with ages and total cholesterol levels indicated.
"+" and "_" indicate the presence and absence of the mutation, respectively. (B) Multiplex
PCR. The five lanes in the polyacrylamide gel contain amplified DNA from the
heterozygous father (1), heterozygous mother (2), heterozygous first child (3),
homozygous second child (4) and normal fetus (5). (C) Gel electrophoresis of Ode I
digested PCR-amplified exon 4 DNA. Lanes: (1) DNA from homozygous daughter (2)
DNA from heterozygous daughter (3) DNA from normal fetus (4) DNA from
heterozygous mother (5) DNA from heterozygous father. [see next page]
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DISCUSSION
This study describes the first prenatal DNA diagnosis that has been performed for FH in
South Africa, approximately ten years after molecular analysis demonstrated that three
LDLR gene mutations are responsible for the disease in 90% of Afrikaners (Leitersdorf
et al., 1989; Kotze et al., 1989). The development of a rapid, nonradioactive screening
method to simultaneously screen for these founder-related mutations D154N, D206E
and V408M, facilitates an improved diagnostic service for FH in South Africa (Kotze et
al., 1995). This method is currently used routinely at four academic institutions in South
Africa, to screen new index cases of European descent for LDLR gene mutations and to
trace the defective gene in families. In the family presented in this study, the value of
such a population-based screening strategy is demonstrated, since the couple who
requested prenatal diagnosis of FH had previously been diagnosed with heterozygous
FH after identification of mutation D206E. Their first-born child is a FH heterozygote and
the second, a homoallelic homozygote.
Analysis of DNA isolated directly from amniotic fluid at the 16th week of gestation, and
subsequently from cultured amniocytes, excluded the presence of mutation D206E in
the foetus. Both allele-specific peR and restriction enzyme analysis methods were
utilised for the diagnosis, since the multiplex assay cannot distinguish between
-,
heterozygote and homoallelic FH homozygote status (Kotze et al., 1995). Sufficient high-
quality DNA is furthermore required for optimal results with the multiplex assay, which
can cause a problem when DNA is extracted from amniotic fluid. Odel digestion,
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however, provides clear distinction between a FH homozygote and heterozygote or an
individual without the D206E mutation. The reason for not using the latter method
routinely in the identification of patients with mutation D206E is firstly, because it is more
cost-effective to simultaneously screen for all three founder mutations in a single
multiplex PCR and secondly, because the small fragment sizes (64- and 42-bp)
generated by Odel digestion in the mutant allele frequently complicates clear distinction
between FH heterozygotes and unaffected individuals. The non-specific band below the
42-bp band in Figure 1C is due to primer dimer.
Due to the sensitivity of the PCR technique, extreme caution should be taken to ensure
that the cells obtained for DNA extraction are foetal in origin and not contaminated by
maternal cells. Since chromosome analyis indicated a male foetus (data not shown) and
mutation D206E previously identified in the mother was absent, further studies to verify
the origin of the DNA analysed were not performed. The finding of a normal lipid profile
(TC 1.4 mmol/I) in cord blood obtained at birth supported the results of the prenatal
diagnosis. Previous studies have indicated that there is a clear distinction in plasma
cholesterol levels between normal and heterozygous FH children at birth (Kwiterovich et
al., 1990).
We believe that prenatal diagnosis of FH and termination of the foetus is justified in
homozygous cases, because the condition is associated with a very high morbidity. This
"
has application in populations where FH is prevalent due to a founder effect, multiple
entries of disease genes into an isolated population or recurrent mutational events. The
Afrikaner population descending from -2000 original settlers who emigrated to the Cape
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of South Africa in the 17th and 18th centuries provide an excellent example of the
founding phenomena (Botha et al., 1983). The fertility rate was high and the population
expanded to the current -4 million of today, with a concurrent increase in specific
defective genes introduced by European settlers. The three LDLR gene mutations
responsible for the high prevalence of FH in Afrikaners have also been shown to
contribute significantly to the FH phenotype in the South African population of mixed
ancestry (Loubser et al., 1999). Molecular analysis of FH in other population groups has
furthermore revealed the presence of founder-type mutations in South African Jewish
(Meiner et al., 1991; Kotze et al., 1997) and Indian communities (Rubinsztein et al.,
1992), as well as in Lebanese (Callis et al., 1998) and Black FH patients (Leitersdorf et
al., 1988; Thiart et al., in press).
Knowledge of the spectrum of causative LDLR gene mutations in the diverse South
African population has led to a population-directed strategy to identify affected families
with FH. This approach provides the opportunity for accurate genetic counseling to
inform families of the importance of mutation screening in other at-risk relatives. Genetic
testing has made pre-clinical diagnosis of FH, including prenatal diagnosis, a reality.
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Familial hypercholesterolaemia (FH) has been a focus of research in South Africa since
its recognition as a common disease among Afrikaners nearly two decades ago (Settel
et al., 1980). Subsequent studies have shown that FH is also prevalent among Indians,
Jews and Coloureds, but rare among Blacks in South Africa. The majority of people with
FH is not diagnosed and therefore is not treated with cholesterol-lowering medication
and modified diets, which may prevent or delay early death from heart attack. The
solution to this problem is directly dependent on the success of finding individuals with
FH. This led to the establishment of the MED-PED project, which is based on the
concept that tracing of the defective gene in close relatives of an index patient would
allow accurate disease diagnosis in approximately 50% of family members (Williams et
al., 1993).
Systematic molecular analysis was used in this study to identify low-density lipoprotein
receptor (LDLR) gene defects in South Africans with a clinical diagnosis of FH, followed
by a family-based DNA screening approach for presymptomatic diagnosis of FH. At
least ten of the 56 different gene defects described to date in the diverse South African
population represents founder type mutations. DNA screening of 792 at-risk family
members for the FH-related mutation identified in 379 index cases, allowed accurate
disease diagnosis in 340 relatives and exclusion of the relevant mutation in 452
individuals. The characteristics of 232 index patients with the fH Afrikaner 1, -2 and -3
mutations are shown in Appendix 1, together with that of 658 relatives screened for the
relevant family-specific mutation. The pedigrees of 106 families where several affected
members were traced via the MED-PED approach are illustrated in Appendix 2. The
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sensitivity and specificity of DNA diagnosis, based on total cholesterol values measured
in family members of index cases recruited for this study, were 88% and 77%,
respectively in Afrikaner families with founder-related LDLR gene mutations. These
values were obtained when applying the 80th percentile for age and gender, the TC cut-
off point found to discriminate between mutation-positive and -negative cases.
The first prenatal DNA diagnosis of FH has been undertaken during the course of this
study, some ten years after it was shown that mutation D206E predominates in the
Afrikaner FH population (Leitersdorf et al., 1989; Kotze et al., 1989, 1991). In the family
analysed both the mother and father were found to be heterozygous for mutation
D206E, while their youngest daughter was shown to be homozygous for the mutation.
The mutation was not detected in DNA amplified directly from amniotic fluid or in
cultured cells of the foetus which led to continuation of the pregnancy. This case
illustrates the application of a DNA-based mutation detection technique as a simple and
rapid diagnostic aid that can be carried out at a relatively early gestational stage.
Prenatal DNA diagnosis of FH aimed at the detection of homozygous cases is an
important consideration in populations and families with molecularly LDLR gene
mutations.
The predominance of at least ten LDLR gene mutations in the local population justifies
population-directed DNA diagnosis of FH in South Africa on a routine basis, particularly
"
since expression of the defective gene measured in biochemical tests does not allow
accurate diagnosis of FH. DNA testing provides definitive tool for family tracing aimed at
pre-clinical diagnosis and preventive treatment of FH. DNA data was used to determine
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the percentage of FH patients that could be diagnosed by clinical criteria. It revealed a
sensitivity value of 88%. The rate at which specific genes for FH are unexpressed in lipid
tests was also determined. A specificity value of 77% was calculated. In the Black
population of South Africa hypercholesterolaemics with lipid profiles compatible with the
diagnosis of heterozygous FH frequently lack xanthomata characteristic of this condition
(Marais and Berger, 1986). These findings provide evidence that FH is probably
underdiagnosed in the South African Black population, most likely as a result of altered
expression of FH-related mutations. It is therefore suggested that clinical/biochemical
criteria for the diagnosis of FH need to be different by country/population and DNA
methods may assist in making a definitive disease diagnosis.
Future prospects of the MED-PED initiative would be to extend this family-based effort
to other treatable genetic diseases, as suggested by Kotze and Callis (1999).
Molecularly uncharacterised patients with a clinical diagnosis of FH will be subjected to
further genomic analysis to identify possible new gene(s) causing autosomal dominant
hypercholesterolaemia (ADH). Recently, a novel locus for ADH was mapped on human
chromosome 1p (Varret et al., 1999; Hunt et al., 1999). Identification and
characterisation of the causative gene may lead to the development of novel therapeutic
strategies targeted at the cause of the disease in a subset of hypercholesterolaemic
families without mutations in the LDLR or apolipoprotein B genes.
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2Abstract
In South Africa the high prevalence of familial hypercholesterolaemia (FH) among
Afrikaners, Jews and Indians due to founder genes is in striking contrast to its
reported virtual absence in the Black population in general. In this study the
molecular basis of primary hypercholesterolaemia was studied in 16 Africans
diagnosed with FH. DNA analysis using three screening methods resulted in the
identification of seven different mutations in the coding region of the low-density
lipoprotein (LDLR) gene in 10 of the patients analysed. These included a 6-bp
deletion (GCGATG) accounting for 28% of defective alleles, and six point mutations
(D151H, R232W, R385Q, E387K, P678L, R793Q) detected in single families. The
Sotho patient with missense mutation R232W was also heterozygous for a de novo
splicing defect 313+1G~A. Several silent mutations/polymorphisms were detected
in the LDLR and apolipoprotein B genes, including a base change (g~t) at
nucleotide position -175 in the FP2 LDLR regulatory element. This promoter variant
was detected at a significantly higher frequency (P<0.05) in FH patients compared to
controls, and occurred in cis with mutation E387K in one family. Analysis of four
intragenie LDLR gene polymorphisms demonstrated that the same chromosomal
background was identified at this locus in the four FH patients with the 6-bp deletion.
Detection of the 6-bp deletion in Xhosa, Pedi and Tswana FH patients suggests that
it is an ancient mutation predating tribal separation approximately 3000 years ago.
3Introduction
Autosomal dominant hypercholesterolaemia (ADH) is most commonly caused by
mutations in the low-density lipoprotein receptor (LDLR) gene causing familial
hypercholesterolaemia (FH), or in the apolipoprotein B (apo B) gene causing familial
defective apo B (FDB).1, 2 These biochemical defects result in the precipitation of
excess cholesterol, and clinical characteristics include tendon xanthomata and
premature coronary heart disease (CHD). The estimated incidence of both FH and
FDB is approximately 1 in 500 in most Caucasian populations.
In the Afrikaner population of South Africa, the prevalence of FH has been
increased to approximately 1 in 70, as a consequence of a founder effect following
the introduction of at least three defective LDLR gene alleles by European settlers.3-5
This is in striking contrast to the apparently low prevalence of FH in the Black
population, reported to have migrated from Central Africa to the South in three main
groups, the Nguni's (Xhosa, Tembu, Swazi and Zulu) along the east coast, the
Sotho's (South Sotho, North Sotho/Pedi, West SotholTswana) who settled further
west on the Transvaal highveld, and the Venda's living in the Northern Transvaal
area.6,7 We suspect that FH is not frequently recognised in Africans due to altered
clinical expression, and not because of a lower mutation prevalence compared to
most other populations. Previous studies have indicated that the mutational
mechanisms giving rise to germ-line mutations is largely a function of the local DNA
sequence environrnent' "
4Since the situation in South Africa is ideal for studies of underlying lipid-
related genetic differences among population groups,11we attempted to identify
Black hypercholesterolaemics to determine the spectrum of mutations in the
promoter and coding region of the LDLR gene and in exon 26 of the apoB gene.
FDB has not previously been studied in the South African Black population, but was
found to be rare in other South African populations, most likely due to a "negative"
founder effect that diluted the frequency of the common apo B3500 mutation in the
immigrants relative to their parent populations."
Subjects and Methods
Subjects
Blood samples were collected from 56 Black patients attending lipid clinics in South
Africa, after obtaining informed consent and ethical approval by the regional Review
Committees. Details on clinical features and ethnicity were provided by the referring
clinicians. Sixteen patients with a diagnosis of "classical" or "probable" FH, including
two FH homozygotes, were selected for extensive mutation analysis for the coding
and promoter region of the LDLR gene and exon 26 of the apo B gene. Blood
samples were also obtained from 38 of their family members (table 1). Classical FH
(12 probands) was defined as the occurrence of pretreatment total cholesterol (TC)
>7 mmol/I, with the presence of tendon xanthomata and/or premature CHD in the
-,
index case or a first-degree relative. Probable FH (4 probands) was defined by the
same pretreatment cholesterol level and primary hypercholesterolaemia and/or
5premature CHD in the family (table 1). DNA samples of the 40 lipid clinic patients
without the FH phenotype, but who had hyperlipidaemia or normal lipid profiles in the
presence of vascular disease, were included for analysis of specific regions of the
LDLR gene. Ninety-six individuals drawn from the same population (19 Pedi's, 21
Sotho's, 27 Xhosa's, 29 Zulu's) were sampled as controls. TC, high-density
lipoprotein cholesterol (HDLC) and triglyceride (TG) determinations and extraction of
genomic DNA were performed using standard methods13Plasma LDL-cholesterol
(LDLC) concentrations were calculated with the Friedewald formula [LDLC=TC-
(HDL+TG/2.18)].14
Mutation detection
Heteroduplex single-strand conformation polymorphism (HEX-SSCP) analysis was
performed in South Africa." and denaturing gradient gel electrophoresis (DGGE) in
Denmark" and Scotland." to screen polymerase chain reaction (PCR)-amplified
genomic DNA for mutations in the LDLR and apo B genes. For HEX-SSCP analysis,
the exon-specific primers described by Jensen et al." were used, while the promoter
region of the LDLR gene was amplified using primers 5'-
GAGGCAGAGAGGACAATGGC-3' and 5'-CCACGTCATTTACAGCATTTCAATG -3'.
Base changes in the promoter region were numbered according to Hobbs et at."
after adding an additional A within the AAM stretch preceding repeat 1, which is
missing from the published sequence." PCR products showing aberrant
electrophoresis patterns were sequenced on both strands with a PCR Product
Sequencing kit (Amersham) and/or an automated sequencer ABI 373A.
6Haplotype analysis
Haplotype analysis using four LDLR gene polymorphisms were performed according
to Theart et al." Microsatellite markersVWA31, F1A1 and TH01 (ProfiIer kit, Applied
Biosystems)were used to test for biological consistency in two families.
Statistical analysis
Allele frequencies were determined by allele counting. Testing for significance of
heterogeneity in mutation frequencies among patient and control groups was based
on the Chi-square and Fisher's exact tests.
Results
Extensive DNA screening of the LDLR gene in 16 Black FH patients, using both the
DGGE and HEX-SSCP screening methods, revealed 6 missense mutations in
individual families and a 6-bp deletion in four probands (table 1).22 The deletion (FH
Cape Town-1), previously described in a Xhosa FH homozyqote." and missense
mutations 0151 Hand R385Q have not (yet) been reported in other populations.
Haplotype Smal+/Stul+/Avall- was associated with the deletion in all three FH
heterozygotes and a homoallelic FH homozygote. Screening of the coding region in
DNA of the four FH patients heterozygous for a base change (g~t) at nucleotide
position -175 of the LDLR gene promoter, resulted in the detection of a recycling-
7deficient mutation E387K19 in the DNA of subject EF. Interestingly, this Pedi proband
was found to be extremely heterogeneous at the DNA level, since a silent C to T
base change was furthermore detected at nucleotide position 1104 in exon 8, in
addition to two silent mutations in the apo B gene. The G to C change in the third
base of codon 3540 (T3540T) and the T to C change in the third base of codon
3552 (T3552T) in the apo B gene have previously been reported in Nigerian and
African American subjects, respectively17 One of the daughters of proband EF (11-3in
fig. 1) carried two copies of the silent apo B mutation at codon 3540. RFLP analysis
indicated that haplotype Smal+/Stul+/Avall-/Ncol+ co-segregated with the -175t
allele in the family (fig. 1). This chromosomal background was also identified in two
of the other probands with the sequence substitution at -175 in the LDLR promoter
region, while haplotype Smal-/Stul+/Avall+/Ncol+ was associated with the t allele in
the Tswana proband (LM), who also carried the T3552T variant in the apo B gene.
In order to determine whether the two mutations identified in each of
probands EF and SH occur in cis or in trans on their respective chromosomes, blood
samples were obtained from additional family members for segregation analysis.
Pedigree analysis in the family of EF demonstrated that mutation E387K and the -
175g~t variant occur on the same chromosome (fig.1). All the family members who
inherited the 387K1-175thaplotype (1-1, 1-2,11-2,11-4,111-2and 111-5)had abnormally
high TC and LDLC levels. Individual 11-2,with a clinical diagnosis of heterozygous
FH, was homozygous for the t allele at nucleotide position -175. This implies that her
deceased father (husband of the index case) also carried the -175g~t promoter
variant, but in the absence of mutation E387K. Her normocholesterolaemic son (111-
81), as well as her brother inherited this paternal chromosome, the latter presenting
with a moderately raised TC value. The proband's son (11-1)and one of her
daughters (11-3) (confirmed by marker studies using highly informative
microsatellites) had moderately raised plasma cholesterol concentrations in the
absence of either the promoter variant or the exonic mutation, indicating that another
unknown factor contributes to the abnormal lipid profile observed in this family. TC
concentrations were found to be very low in the general Black population
(approximately 3 mmol/I) comparedwith other South African groups.24,25
DNA screening of the 53-year old father of proband CK, diagnosed with
homozygous FH, revealed homozygosity for the t allele at nucleotide position -175.
His TC and LDLC levels were 6.11 mmoiII and 4.29 mmoIII, respectively, which is
comparable to that of a FH heterozygote. Plasma TG and HDLC concentrations were
1.49 mmol/I and 1.14 mmoIII, respectively, and the only clinical feature indicative of
hyperlipidaemia in this obligate FH heterozygote was corneal arcus.
HEX-SSCP analysis indicated that the splicing defect identified in exon 3
represents a de novo event in the family of SH, since it was not present in any of his
close relatives analysed. Familial relationship was illustrated by transmission of the
exon 5 mutation (R232W) from the father (72 years, TC 4.1 mmol/I), and was further
substantiated by marker studies using three highly informative microsatellites (data
not shown). Mutation R232W was absent in the normocholesterolaemic brother (30
years, TC 3.5 mmol/I) and sister (42 years, TC 3.3 mmol/I) of the proband. Their
-,
mother aged 62 years presented with a TC level of 2.9 mmol/I. It was therefore not
possible to determine whether the splice mutation occurred in cis in the proband on
9the paternal chromosome bearing mutation R232W, or in trans on the normal
maternal chromosome.
Subsequent DNA screening of 96 control individuals from the general Black
population comprising 56 Nguni's (27 Xhosa's, 29 Zulu's) and 40 Sotho's (19 Pedi's,
21 Sotho's) resulted in the identification of 6 individuals [4 Nguni's (1 Xhosa, 3
Zulu's) and 2 Sotho's (1 Pedi, 1 Sotho)) heterozygous (6%) for the -175t allele.
Although the number of patients analysed is small, the frequency of this allele
appeared to be higher within each tribal group (2/6 Nguni's and 2/10 Sotho's with
FH) compared to the controls (4/56 Nguni's and 2/40 Sotho's). An overall statistically
significant difference (P<0.05) was observed between the presence of the rare t
allele in the general Black population (0.03) compared to its frequency of 0.13 in
the patients diagnosed with classical or probable FH (x2=5.916, 1df, P=0.0149). We
furthermore detected 5 carriers of the -175g~t polymorphism among 40 lipid clinic
patients without the FH phenotype (13%), demonstrating an intermediate allele
frequency of 0.06. This was not significantly different from the frequencies observed
in the FH (x2=1.326, 1df, P=0.249) or control (x2=1.474, 1df, P=0.224) groups.
Variant -175g~t was also detected in 1/47 DNA samples of control individuals from
the Venda tribe studied by Ehrenborg et al.25 while absent in more than 300
Caucasians screened."
Discussion
10
Numerous LDLR gene mutations (>600) have been identified in FH patients world-
wide, but genetic data on Black African populations are rare.19• 22. 23. 27 A striking
finding is that a 6-bp deletion predominate in a small number (5/18) of FH patients 19.
23,28, this study identified in the South African Black population, where this lipid disorder
is thought to be rare. This deletion in exon 2 removes an aspartic acid and a glycine
from the first cysteine-rich ligand binding repeat of the LDLR, and impairs its
transport but not lipoprotein binding in fibroblasts.f Frequent detection of a
deleterious mutation can be due to consanguinity, recurrent mutational events,
genetic drift, founder gene effect, multiple introduction of the mutation into a
population or heterozygote advantage.
The 6-bp deletion identified originally in a homoallelic Xhosa FH
hornozyqote," and now also in a homozygous Pedi and three FH heterozygotes
(Pedi and two Tswana's) on the same haplotype, have not (yet) been reported in
other populations. These findings largely exclude the likelihood of a recurrent
mutational event due to slipped mispairing or multiple entries of the deletion-
mutation into the Black population. Detection of the deletion in different tribes
suggests that it originated in Africa approximately 3000 years ago prior to tribal
separation." Although FH patients with the deletion may therefore be distantly
related, family ties cannot at present explain its relatively high prevalence among
Black FH patients. The apparently low prevalence of FH in South African Blacks and
the large population size furthermore argue against a founder effect. It is, however,
possible that the deletion-mutation was propagated and inherited within a small
group of people who later evolved separately into different African tribes. Another
11
plausible explanation is that this deleterious deletion-mutation may be associated
with a selective advantage in Africa. Already in 1990 Hobbs and co-workers" noted
that the presence of several founder mutations in different South African population
groups4,31may be indicative of a Darwinian selection that favours the heterozygous
state in this region of the world. Since the most likely selective agent in Africa would
be infectious diseases, the finding that LDLR-deficient mice are protected against
lethal endotoxemia and severe gram-negative lntections" supports the likelihood of
such an evolutionary selection mechanism conferring a survival advantage. In
addition to binding and inactivating endotoxin, lipoproteins also bind certain viruses
and inhibit their infectivity33
Although the family data presented in this study demonstrate that the -
175g~t polymorphism residing in a cis-acting element in the LDLR promoter" does
not cause the FH phenotype in affected individuals, further studies are warranted to
investigate the likelihood that this variant may influence disease expression. The
possibility that the significantly higher frequency of the -175g~t promoter
polymorphism in South African Black FH patients compared to controls (P<0.05) is
caused by linkage disequilibrium with another downstream mutation causing the FH
phenotype, was excluded by haplotype studies demonstrating that the rare t allele
was associated with different LDLR haplotypes. This allele furthermore co-
segregated with missense mutation E387K in one family. These different
chromosomal backgrounds may be the result of recombination events, reflecting the
-,
age of the -175g~t variant. Compared to Caucasians, Blacks are considered older
in evolutionary terms" and can therefore be expected to have accumulated variation
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over longer times. It is possible that the -175g-+t polymorphism did not spread to
other parts of the world, thereby explaining its apparent absence in Caucasian
populations.": 36, this study The African origin of the -175g-+t variant was confirmed by
detection of the rare t allele at a low frequency in control DNA samples obtained
from Nigerians and African-Americans." African Americans has originated mostly
from the western African coast and arrived in North America between the 16th and
19th centuries.
One Sotho proband was heterozygous for a known splicing defect in intron 3
(313+1G-+A) and for the R232W mutation in exon 5. In all the patients with mutation
313+1G-+A studied to date, the splicing defect is associated with a clinical picture of
severe hypercholesterolaemia and early CHD.37, 38 Patient SH had a TC
concentration of 13 mmol/I, but it is uncertain whether this high level is solely due to
the 313+1G-+A mutation or whether there is an additional effect of the downstream
R232W mutation. Family studies could not rule out the possibility of a double
mutation, but demonstrated that the splicing defect is the consequence of a de novo
mutation. None of the family members of SH were hypercholesterolaemic, including
his 72-year old father (LDLC 1.9 mmol/I), who was heterozygous for mutation
R232W. This finding indicates that R232W does not affect LDLR function or,
alternatively, that clinical expression of this missense mutation is altered by other
genetic and/or environmental factors.
Although the identified missense mutations have not been characterised
further, they are likely contributors to the FH phenotype in our patient sample, since
all the codon changes involve conserved amino acids and were not detected in the
13
normal population. Screening for mutations causing FDB16, 17, 39 resulted in the
identification of two silent mutations T3540T and T3552T (data not shown)
previously described in a Nigerian and African American subject, respectively."
Failure to identify disease-related mutations in all the patients studied may be due to
limitations imposed by the screening techniques used, clinical misdiagnosis of FH, or
mutations in other genes causing the ADH phenotype.4Q,41
Both the Zulu and Pedi patients clinically diagnosed with homozygous FH
presented with relatively low pretreatment TC levels « 15 mmol/l) for this severe
condition1 and neither have yet suffered from CHO. The relatively mild expression of
homozygous FH in these subjects largely precludes an estimation of the prevalence
of heterozygous FH in the South African Black population based on the prevalence
of homozygous FH. Elevated plasma cholesterol levels causing FH in a family
frequently remain undetected until the occurrence of coronary events or clinical
signs indicative of FH is observed in one or more family members. This may
particularly be the case in the South African Black population, as
hypercholesterolaemics with lipid profiles compatible with the diagnosis of
heterozygous FH frequently lack xanthomata characteristic of this condttlon.": this study
None of the FH heterozygotes with the relatively severe 6-bp deletion in exon 223
presented with CHO. These findings provide evidence that FH is probably
underdiagnosed in the South African Black population, most likely as a consequence
of altered expression of FH-related mutations. This may be due to interaction with
other genetic and environmental factors, including a prudent diet." Data provided by
us and others43-45 therefore suggest that clinical/biochemical criteria for the diagnosis
14
of FH need to be different by country/population and that DNA methods may assist in
making a definitive disease diagnosis.
Table 1
Characteristics of African probands analysed for LDLR and apo B gene mutations
Index Ancestry Sex Age TC TG HOL LOL Clinical LOLR gene Apo B gene Relatives
(mmol/I)" sequence changes sequence Tested
changes
CM Xhosa F 52 8.5 2.7 1.5 5.8 CHO R793Q 0
MX Xhosa M 50 10.8 2.0 0.9 9.0 Arc, Xan -175g--j>t 0
AN Swazi F 58 10.1 0.9 1.3 8.4 Arc, Xan, CHO 0151H 0
AS Swazi M 49 8.0 1.0 2.1 5.4 Arc, CHO P678L 0
AMs Swazi/Zulu F 56 8.3 1.5 1.9 5.7 Arc 11
CI('l Zulu M 26 13.8 0.8 1.3 12.1 Arc, Xan -175g--j>t 1
SH Sotho M 33 12.7 2.2 1.2 10.5 Arc, Xan 313+1G--j>A; R232W 4
RK Sotho M 58 10.7 2.3 1.0 8.6 CHO R385Q 0
KNu Pedi F 32 14.9 0.8 1.4 13.1 Arc, Xan 6-bp del, 6-bp del 0
EF Pedi F 56 13.1 1.1 1.2 11.4 Arc, PVD, CHO E387K; -175g--j>t; C347C T3552T;T3540T 10
LP Pedi F 61 9.4 0.8 0.9 8.1 Arc, Xan 6-bp del 3
CNa Pedi F 57 7.4 2.6 0.9 5.3 Arc, PVO 6
RMs PedilTswana F 54 10.8 0.4 1.3 9.3 Arc, ?Xan 3
LMa Tswana F 56 6.1 1.8 1.8 3.5 Arc, CHO -175g--j>t T3552T 0
RL Tswana F 30 9.3 0.8 1.7 7.2 Arc, Xan 6-bp del 0
CS Tswana F 47 7.9 0.7 1.7 5.9 Arc 6-bp del 0
""The maiority of mutations summansed In this table were Included In a recent mutation update.
Reference plasma cholesterol concentrations in the general Black population are given in ref. 24
TC, total cholesterol; TG, triglycerides, HOL, high-density lipÓprotein cholesterol; LOL, low-density lipoprotein cholesterol; CHO, coronary heart
disease, PVO, peripheral vascular disease, Arc, arcus corneal is; Xan, xanthomata.
"Probable FH; DClinical FH homozygotes; CPretreatment concentrations, except for proband LM for whom pretreatment levels was not available
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Figure 1 Pedigree of proband EF (arrow) clinically diagnosed with heterozygous FH.
Clinical, biochemical and genetic data are provided for individuals of whom DNA
samples were available. Those with elevated plasma cholesterol levels are indicated
by dark- (mutation-positive for E387K) and shaded symbols. The presence (+) or
;
absence (-) of LDLR gene mutations and recognition sites for Smal, Stul, Avail and
Ncol are indicated.
II
2 5
III 26 515 13 31 12 7Age (years) 62 57 38 35
2.8 6.1 7.4 3.5 5.2 8.6 7.3TG (mmol/I) 9.3 13.1 5.8 10.5
1.8 . 4.8 5.2 1.9 4.0 7.2 6.2LOLC (mmol/I) 5.9 11.4 2.8 8.8
0.8 0.8 1.4 1.3 0.9 1.0 0.8HOLC (mmol/I) 3.0 1.2 2.4 1.1
0.4 1.1 1.7 1.6 0.6 0.8 0.7TG (mmol/I) 0.9 1.1 1.3 1.5 +
Xanthomas - ,
GVO/PVD PVO +- +-
E387K +- +- +- + - + - + -
-175GIT + - + - + - ++ + - + -
++ ++ ++ ++ ++
Sma I ++ ++ ++ ++ ++ ++
+- ++ ++ + - ++
Stu I ++ ++ ++ ++ ++ ++
Ava II
++ ++ ++ ++ ++Nco I ++ ++ ++ ++ ++ ++
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